Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Gonadotropin-releasing hormone Stories

2012-11-01 07:31:01

QUÉBEC CITY, Nov. 1, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its Director of Preclinical Development, Babette Aicher, PhD, will be making a poster presentation on preclinical results for disorazol Z cytotoxic conjugates, such as AEZS-125, in ovarian cancer, at the upcoming 24(th) EORTC-NCI-AACR (ENA) Symposium on "Molecular Targets and Cancer Therapeutics", which will be held November 6-9, 2012 in...

2012-08-28 02:28:12

BATON ROUGE, La., Aug. 28, 2012 /PRNewswire/ -- Esperance Pharmaceuticals today announced the completion of the run-in cohort of its Phase 2, randomized, multi?center trial of EP?100 in combination with paclitaxel for patients with advanced ovarian cancer. EP?100 is a targeted membrane?disrupting peptide (tMDP) designed to seek and destroy cancer cells that over?express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over?expressed in a wide range...

2012-08-26 22:22:01

LAUSANNE, Switzerland, August 27, 2012 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced that the first patient has been enrolled in an open-label phase III study to investigate the efficacy, safety, and pharmacokinetics of the sustained release triptorelin pamoate 22.5 mg 6-month-formulation...

2012-08-10 02:48:45

Women with uterine fibroids larger than 10 cm have a new nonsurgical treatment choice —hormone acting drugs followed by uterine artery embolization, a new study shows. The new treatment option can replace hysterectomy, which leaves women infertile. The study, conducted at the Yonsei University College of Medicine in Seoul South Korea, included 40 women with 10 cm or larger uterine fibroids. Twelve of the women received gonadotropin-releasing hormone (GnRH) agonists to shrink their...

2012-06-05 02:28:04

ABBOTT PARK, Ill., June 5, 2012 /PRNewswire/ -- Abbott (NYSE: ABT), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the initiation of a pivotal Phase 3 clinical trial designed to evaluate the safety and efficacy of elagolix in female patients with endometriosis. Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist. "Endometriosis can be a debilitating disease that affects millions of women around the world and the exploration of new...

2012-06-04 02:27:12

BATON ROUGE, La., June 4, 2012 /PRNewswire/ -- Esperance Pharmaceuticals presented its Phase 1 study of EP-100, a novel targeted membrane?disrupting peptide (tMDP) in advanced solid tumors at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. EP?100 is designed to seek and destroy cancer cells that over?express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over?expressed in a wide range of cancers. The Phase 1...

2012-05-17 10:25:26

BATON ROUGE, La., May 17, 2012 /PRNewswire/ -- Esperance Pharmaceuticals today announced that it has begun enrollment of a Phase 2, randomized, multi-center trial of EP-100 in combination with paclitaxel for the potential treatment of advanced ovarian cancer. EP-100 is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over-expressed in a wide...

2011-08-31 20:18:35

A new birth control vaccine for white-tailed deer – a growing nuisance in urban areas for gardens and landscaping – eliminates the dangerous reproductive behavior behind the annual autumn surge in automobile-deer collisions. The vaccine, just becoming commercially available in some states, was the topic of a report here today at the 242nd National Meeting & Exposition of the American Chemical Society (ACS). Named GonaCon, the vaccine also shows promise for reducing or...

2011-05-16 10:02:00

WASHINGTON, May 16, 2011 /PRNewswire/ -- A poster entitled, "Time to Progression in Patients with Prostate Cancer: A Comparison of Continuous Degarelix versus Degarelix Following Leuprolide Treatment," is being presented at the American Urological Association 2011 meeting by E. David Crawford, MD, head of the Section of Urologic Oncology at the University of Colorado Health Sciences Center in Denver, and lead study investigator. The full manuscript has just been accepted and will be...

2011-05-11 12:50:38

Gonadotrophin-releasing hormone antagonists as effective as agonists with fewer serious harmful effects With new information available, authors of a Cochrane Systematic Review have revised their conclusions about the relative effectiveness of two different treatments used to help women become pregnant. They now conclude that giving women gonadotrophin-releasing hormone (GnRH) antagonists leads to similar live-birth rates compared with GnRH agonists. Previously they had concluded that women...